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Abstract
The regulatory mechanisms governing the cell cycle progression of hematopoietic stem cells (HSCs) are well characterized,
but those responsible for the return of proliferating HSCs to a quiescent state remain largely unknown. Here, we present
evidence that CD81, a tetraspanin molecule acutely responsive to proliferative stress, is essential for the maintenance of
long-term repopulating HSCs. Cd81
2/2 HSCs showed a marked engraftment defect when transplanted into secondary
recipient mice and a significantly delayed return to quiescence when stimulated to proliferate with 5-fluorouracil (5FU). In
addition, we found that CD81 proteins form a polarized patch when HSCs are returning to quiescence. Thus, we propose
that the spatial distribution of CD81 during the HSC recovery phase drives proliferative HSC to quiescence, and is important
to preserve the self-renewal properties. Here, we show that lack of CD81 leads to loss of HSC self-renewal, and the clustering
of CD81 on HSC membrane results in deactivation of Akt, which subsequently leads to nuclear translocation of FoxO1a.
Thus, CD81 functions as part of a previously undefined mechanism that prohibits excessive proliferation of HSCs exposed to
environmental stress.
Citation: Lin KK, Rossi L, Boles NC, Hall BE, George TC, et al. (2011) CD81 Is Essential for the Re-entry of Hematopoietic Stem Cells to Quiescence following Stress-
Induced Proliferation Via Deactivation of the Akt Pathway. PLoS Biol 9(9): e1001148. doi:10.1371/journal.pbio.1001148
Academic Editor: Connie J. Eaves, B.C. Cancer Agency, Canada
Received January 20, 2011; Accepted July 29, 2011; Published September , 2011
Copyright:  2011 Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: KL was supported by T32-DK064717, T32-AI07495, and T32- DK60445. This work was also supported by NIH grants DK58192, EB005173, P50CA126752,
and HL08100 as well as the American Heart Association (0740020N). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: goodell@bcm.edu
Introduction
Hematopoietic stem cells (HSCs), which represent around 1/
10
4 to 1/10
5 bone marrow cells, can proliferate to replenish the
hematopoietic system after its exposure to environmental stresses
such as infection, ablative chemotherapy, or irradiation. The stem
cell compartment is maintained by self-renewal, in which HSCs
generate daughter cells that retain stem cell function after cell
divisions. The delicate balance maintained between differentiation
and self-renewal necessitates a constellation of intrinsic and
extrinsic regulatory mechanisms that are still not well understood.
The vast majority of HSCs possess a dormant phenotype (G0
phase of the cell cycle) [1] and slow cycling kinetics (prolonged G1
phase) [2], enforced by regulatory mechanisms that inhibit cell
cycle progression from a quiescent stage to active proliferation [3].
In the face of proliferative stimuli, however, these controls are
overridden to allow the stem cells to perform their regenerative
functions, posing an intriguing question: how do the self-renewing
HSCs re-enter a quiescent state? Although extrinsic signaling from
cytokines has been proposed to facilitate HSC quiescence [4–6],
the mechanisms that intrinsically dictate cell cycle exit in HSCs
remain largely undefined.
We previously identified several cohorts of genes that are
preferentially expressed in HSCs during proliferative and
quiescent states [7], and are thus candidates for playing a role in
regulation of self-renewal. The gene encoding CD81 (also called
Tapa-1), a cell surface transmembrane protein that belongs to the
tetraspanin family, emerged from that study as one of the most
consistently upregulated molecules in HSCs exposed to prolifer-
ative stress [7]. This protein is found in a variety of tissues and has
been shown to regulate cell migration, adhesion, and fusion, as
well as proliferation and pathogen entry [8]. It is widely expressed
in the murine hematopoietic system [9], where its roles include
cell-cell interaction, lymphocyte activation, and leukocyte adhe-
sion [10]. This functional versatility and the upregulated
expression pattern of Cd81 in proliferating HSCs led us to
hypothesize that this tetraspanin molecule has a specific function
in HSC fate determination, particularly during active stem cell
regeneration and proliferation.
Serial competitive transplantations provide extreme prolifera-
tive stress for HSCs, in which the functional integrity of HSCs has
to be delicately maintained and tightly controlled such that an
imbalance of cell cycle progression (reviewed in [3]) or
uncontrollable level of reactive oxygen species (ROS) [11]
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13compromise the ability of HSCs to regenerate. Akt/Pkb, a serine/
threonine kinase, is found to be a key regulator in maintaining
HSC integrity. Constitutive activation of Akt in HSCs leads to
HSC hyperproliferation and loss of HSC engraftment in primary
competitive transplantation (the first round of transplantation)
[12], a similar phenotype to that of HSCs lacking Pten, a negative
regulator in the Akt pathway [13]. HSCs lacking both Akt1 and
Akt2 show an engraftment defect in the third competitive
transplantation (a third round of transplantation using donor-
derived HSCs or bone marrow) [14]. Interestingly, loss of
molecules downstream of Akt, such as Atm, FoxOs, and p21,
results in similar phenotypes. Atm
2/2 HSCs failed to engraft long-
term in competitive transplantation assays [15]. HSCs lacking
FoxO3a show a significantly decreased engraftment in the
secondary competitive transplantation [16], while Foxo1/3/4
2/2
HSCs present a much more severe engraftment defect such that
they fail to engraft in the primary transplantation [17]. In addition,
HSCs lacking p21
Cip1/Waf1, a cyclin-dependent kinase inhibitor
downstream of Akt, exhaust at the 4
th transplantation [18].
Here we show, by using Cd81
2/2 HSCs in competitive
transplantation assays and monoclonal antibody treatment to
induce CD81 clustering on the HSC membrane, that CD81 paces
the return of proliferating HSC to a quiescent state. We also
demonstrate that CD81 mediates this effect by downregulating the
activation state of Akt and subsequently promoting FoxO1a
translocation into the nucleus, where it induces cell cycle
suppression. Moreover, with the treatment of perifosine, an Akt
inhibitor, the engraftment defect of Cd81
2/2 HSCs is corrected,
indicating that CD81 is involved in maintaining HSC function
integrity through Akt pathways. In addition, we show here the
expression of p19, a downstream CDK inhibitor of FoxO proteins
[19], is significantly lower during the regeneration of Cd81
2/2
HSCs. In addition, the expression of oxidative responsive genes is
significantly decreased in quiescent Cd81
2/2 HSC post-regener-
ation, suggesting Cd81
2/2 HSCs are more susceptible to reactive
oxygen species (ROS), which may contribute to their compro-
mised function.
Results
Self-Renewing HSCs Express CD81 during Stress-Induced
Proliferation
In our previous study [7], Cd81 mRNA was sharply upregulated
in HSCs (SP
KLS, c-Kit
+ Lin
2 Sca-1
+ purified from the Side
Population of mouse bone marrow cells [20]) after treatment with
5-flurouracil (5FU), a cytotoxic drug that induces HSCs to
proliferate. The entire side population (SP) compartment expand-
ed markedly after 5FU induction (Figure S1A), exhibiting a
heterogeneous surface expression of CD48, a known marker of
HSC differentiation that is absent in unperturbed HSCs [21,22],
and CD81. The presence or absence of CD81 and CD48 defined
three subpopulations of the 5FU-stimulated, heterogeneous SP
cells (Figure S1B), and the pattern of expression provided an
opportunity to further assess the apparent association between
CD81 and proliferating HSCs. Interestingly, the CD81
+CD48
2
subpopulation was preferentially distributed toward the lower SP
(Figure S1B), associated with the most primitive long-term HSC
activity [20,21], consistent with the hypothesis that CD81 plays a
functional role in HSC self-renewal. To further test whether CD81
expression was associated with HSC activity after 5FU treatment,
we compared the ability of the CD81
+ or CD81
2 fractions of SP
cells to reconstitute hematopoiesis, using competitive transplanta-
tion assays. At 5, 13, and 20 weeks post-transplantation into
lethally irradiated mice, the CD81
+CD48
2 donor cells showed
significantly greater repopulating activity than the CD81
2CD48
+
or the CD81
+CD48
+ fractions (Figure 1A; the number of
CD81
2CD48
– cells is insignificant). Because CD48 expression is
associated with differentiation [22], this suggests that these
markers delineate a transition between self-renewal and differen-
tiation, with CD81 expression associated with sustained HSC
activity. More interestingly, among the three subpopulations,
CD81
+CD48
2 are the only cells presenting a rapid return to
quiescence (Figure 1B), suggesting that HSCs tend to return to
quiescence once sufficient progeny are generated.
Further evidence for a role of CD81 in HSC self-renewal came
from studies that monitored the expression of CD81 protein by
HSCs (SP
KLS) over the course of 5FU treatment, using an anti-
CD81 monoclonal antibody, EAT2. The proliferative response of
HSCs to a single dose of 5FU (150 mg/kg) has been established:
HSCs begin to proliferate late on day 1 post-treatment and reach
maximal proliferation on day 6, returning to quiescence after day
7 [7]. The expression of CD81 correlated closely with the
proliferation kinetics of the HSCs (as defined both SP
KLS and
CD150
+CD48
2c-Kit
+Sca-1
+Lin
2). In contrast to its low expres-
sion by unstimulated HSCs (5FU-Day 0), the CD81 protein was
detected in abundance on days 2, 5, and 8 post-treatment, with a
return to background levels by day 11 (Figure 1C).
Lack of CD81 in HSCs Leads to a Secondary Engraftment
Defect
The timing of CD81 expression on proliferating HSCs
suggested a role for this molecule in HSC self-renewal, a
prediction we sought to test using HSCs purified from CD81
deficient mice (Cd81
2/2) [23] and wild-type HSCs transplanted
into lethally irradiated mice. In the primary competitive
transplantation assays (Figure 2A), the engraftment capacity of
Cd81
2/2 HSCs did not differ appreciably from that of the wild-
Author Summary
Hematopoietic stem cells (HSCs) remain dormant in the
bone marrow until needed to replenish the hematopoietic
system, at which point they are stimulated to proliferate
extensively, undergoing both regeneration (self-renewal)
and differentiation. Self-renewal is key to maintaining an
adequate HSC reserve, and return to dormancy after such
stimulation is critical, yet still poorly understood. In this
study, we report that CD81, a transmembrane organizing
protein, is a novel regulator involved in HSC self-renewal.
Transplanting HSCs into mice that are lethally irradiated to
remove their native HSCs stimulates the transplanted HSCs
to proliferate to replenish the hematopoietic system,
allowing us to examine whether and how HSCs return to
quiescence. HSCs lacking CD81 take longer to return to
quiescence after such stimulation, resulting in reduced
stem cell function. Conversely, forced CD81 membrane
clustering, using an antibody, promotes early return of
proliferating stem cells to quiescence and nuclear locali-
zation of FoxO1a, a key protein that mediates the cell cycle
arrest. CD81 clustering also constrains Akt activity, which
orchestrates multiple pathways such as cell proliferation
and responses to reactive oxygen species. Treatment of
Cd81-deficient HSCs with an Akt inhibitor, perifosine,
which bypasses the requirement for CD81 in this process,
rescues the delay defect of Cd81-deficient HSCs. Together,
our data demonstrate that CD81 is critical to maintaining
the functional integrity of HSCs during regeneration, and it
is acting through Akt to influence its downstream
pathways that govern cell cycle progression.
CD81 Is Essential for HSCs Returning to Quiescence
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lineages (Figure S2A). To test whether Cd81
2/2 HSCs were able
to generate HSCs in the transplant recipients (self-renewal) we
purified HSCs from the primary recipients and examined their
function. Despite their ability to differentiate in vitro, as
determined by methycellulose assays (Figure S2B), they engrafted
secondary transplant recipients only marginally (Figure 1B),
indicating a defect in their ability to self-renew. In addition,
Cd81
2/2 and wild-type HSCs showed nearly identical properties
in homing assays performed over the first 24 hours of secondary
transplantation (Figure S2C), indicating that the hematopoietic
repopulation defect shown by the Cd81
2/2 HSCs is independent
of their response to chemokine-guided homing to stem cell niches.
It is worth noting that the un-challenged Cd81
2/2 bone marrow
not only presents with comparable stem cell composition and
cellularity (unpublished data), but the primary transplantation with
whole bone marrow cells also exhibited no defect in engraftment
(unpublished data), indicating that the defect found in Cd81
2/2
HSC is specific to the HSC progeny that have gone through
self-renewal.
Cd81
2/2 HSCs Show Normal Proliferation During
Homeostasis But Are Delayed in Returning to Quiescence
after Proliferative Stress
To elucidate the mechanism underlying defective engraftment
by Cd81
2/2 HSCs, we considered that a hyperproliferation
phenotype leading to depletion of the stem cell pool is often linked
to ineffective secondary or serial transplantations [18,24,25]. As a
molecule highly expressed primarily during the short window of
HSC proliferation, we reasoned that CD81 may specifically exert
its function only when cells encounter proliferative stress. We
therefore challenged primary recipients of transplantation with
wild-type or Cd81
2/2 HSC transplants with one dose of 5FU
(150 mg/kg), and evaluated the proliferative status of the donor-
derived HSCs. Under steady-state conditions in the absence of
proliferative stress, similar fractions of Cd81
2/2 and wild-type
HSCs were proliferating, determined by bromodeoxyuridine
(BrdU) labeling assays (Figure 3A). Comparable proportions of
Cd81
2/2 and wild-type HSCs were also proliferating on day 4
after 5FU treatment, suggesting that CD81 does not participate in
the early phase of HSC proliferation stimulated by the drug
(Figure 3B). Thereafter, the Cd81
2/2 cells showed only a modest
decline in proliferative activation on day 8 after 5FU treatment,
while their wild-type equivalents began a relatively rapid return to
quiescence (Figure 3B). Interestingly, Cd81
2/2 HSCs were able to
return to a comparable level of quiescence in the later stage of
recovery (5FU-Day12), indicating that CD81 functions to facilitate
the recovery of HSCs in the face of 5FU stimulation or other types
of proliferation stress. Therefore, it is evident that the defective
engraftment in the secondary transplantation is not an exhaustion
of Cd81
2/2 HSCs through over-proliferation. Rather, it is a loss of
functional integrity with signs of uncoordinated cell cycle
progression.
A Distinct Clustering Pattern of CD81 Is Associated with
HSCs Returning to the Quiescent State
CD81 is a tetraspanin molecule that is believed to organize
membrane domains for signaling molecules and therefore is
involved in a variety of signaling pathways downstream of these
molecules. We therefore sought to determine if CD81 forms
discrete domains in proliferating HSCs. We identified a distinct
clustering pattern of the molecule on day 8 after 5FU treatment
(Figure 3C,D), which was not observed for other membrane
proteins, such as CD29 (unpublished data). CD81 was identified as
an anti-proliferation target from monoclonal antibody screenings
[26,27]. It has been reported that engagement of CD81 by a high
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Figure 2. CD81 is essential for maintaining HSC self-renewal. (A)
Cd81
2/2 HSCs show comparable engraftment capacity in primary
competitive transplantation assays, in which 300 HSCs (CD45.2
+SP
KLS)
were transplanted with 2.2610
5 wild-type (WT) competitors (CD45.1)
into lethally irradiated mice (CD45.1
+). Peripheral blood engraftment
was measured at the indicated time points. Mean values 6 50 are
shown (n=3). (B) Cd81
2/2 HSCs showed only minimal levels of
engraftment in secondary competitive transplantation assays, in which
300 donor-derived HSCs (CD45.2
+SP
KLS) were purified from the primary
recipients 21 wk after primary transplantation and transplanted along
with 2610
5 wild-type competitors into lethally irradiated mice. Mean
values 6 SD are shown (n=10, **p,0.01).
doi:10.1371/journal.pbio.1001148.g002
Figure 1. CD81 marks regenerating HSCs that are returning to quiescence. (A) Competitive transplantation assay shows that among the SP
cells from the 5FU-treated mice, the CD81
+CD48
2 fraction contains most of the stem cell activity, compared with that of the CD81
+CD48
+ and
CD81
2CD48
+ fractions. In this assay, 300Lin
2SP (Side Population) cells expressing the indicated markers were transplanted with 2.5610
5 whole bone
marrow competitors. The test donor population was derived from CD57Bl/6-CD45.2 mice, while the competitors and recipients were C57BL/6-CD45.1
mice, enabling us to determine the contribution of HSCs to peripheral blood production, using flow cytometry to detect the CD45.2 marker. The
values are means 6 SD (n=5 per group per time point), **p,0.01, *p,0.05. (B) CD81
+CD48
2Lin
2SP cells show the least expression of Ki-67, a
proliferation antigen, at each 5FU time point tested, indicating that CD81
+CD48
2 cells are the cells returning to quiescence most rapidly among the
Lin
2SP cells. For each time point, femurs and tibias from 3 to 4 mice were collected in each experiment, and at least two independent experiments
were performed for each time point. (C) Expression of CD81 by HSCs (SP cKit
+Lin
2Sca1
+,S P
KLS) is upregulated when the stem cells are proliferating in
response to 5FU stimulation (shown here are 5FU-Day2 and 5FU-Day5). CD81 is expressed at background levels in quiescent HSCs (5FU-Day0 and
5FUDay11), but is upregulated during proliferation (starting at 5FU-Day2).
doi:10.1371/journal.pbio.1001148.g001
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proliferation [28]. To test whether clustering of CD81 on the cell
membranes facilitates quiescence in HSCs, we used an anti-CD81
monoclonal antibody, EAT2 [29], to engage signaling down-
stream of this tetraspanin molecule. Notably, the antibody-treated
proliferating HSCs (5FU-Day7) harbored CD81 protein clustered
in patches on the cell membrane, while in the isotype control-
treated HSCs, the CD81 proteins were scattered throughout the
membrane (Figure 4A). By measuring the area of clustering, we
found that the EAT2 treatment promotes tighter clustering of
CD81 protein on proliferating (5FU-Day7) HSC (Figure 4B), a
day earlier than CD81 naturally coalesces (Figure 3C,D). Finally,
binding of the anti-CD81 antibody triggers an early exit of HSCs
from the cell cycle, as a significant fraction of HSCs treated with
the EAT2 antibody return to quiescence (Figure 4C,D). Thus,
cross-linking CD81 molecules with monoclonal antibodies on
proliferating HSCs (5FU-Day7) recapitulated what we observed
on HSCs in later proliferating stages when returning to quiescence
(5FU-Day8), and the clustering pattern of CD81 on HSCs
correlated with a quiescence phenotype.
Manipulating the Distribution of Membrane CD81 Leads
to Changes in Akt-FoxO Activity
When brought into close proximity, tetraspanin molecules are
thought to form microdomains that constrain other resident
membrane proteins, ultimately affecting downstream signaling
pathways [10]. We therefore investigated the downstream
signaling cascade initiated by CD81 clustering in proliferating
HSCs, first testing the activation state of ERK (MapK1), p38
(MapK14), JNK (MapK8), and Akt, which were reported to
participate in signaling pathways downstream of CD81 after its
stimulation by various means [30,31]. At 1 h after stimulation with
EAT2 antibody, only Akt showed a significant reduction (20%) in
its phosphorylation state in response to antibody-induced CD81
clustering (judged by the ratio of median fluorescence intensity of
phospho-Akt in EAT2-treated HSC to that in isotype-control
antibody-treated HSCs) (Figure 5A). More importantly, the
expression of CyclinD1, a cell cycle regulator downstream of
Akt, was found to decrease by 30% (Figure 5A). This suggests that
EAT2-induced CD81 clustering on HSCs leads to a downregu-
lation of Akt activity, which subsequently represses HSC
proliferation via CyclinD1 reduction.
The FoxO transcription factors, which are suppressed by Akt
during cell proliferation, are essential for HSC self-renewal [32].
Activated Akt phosphorylates FoxO proteins, which are then
restricted from entering the nucleus. A return of HSCs to
quiescence should thus involve deactivation of Akt and nuclear
entrance by FoxOs. To examine whether the Akt deactivation we
observed resulted in nuclear localization of any FoxO proteins and
suppression of HSC proliferation, we utilized Imagestream flow
cytometry [33] to visualize the localization of FoxO1a and
FoxO3a and to quantify the number of HSCs with FoxO nuclear
localization during FACS analysis. We discovered that FoxO3a
was localized in the nucleus regardless of antibody treatment
(Figure 5B), while FoxO1a translocated from the cytoplasm to the
nucleus after anti-CD81 antibody stimulation (Figure 5B). The
nuclear localization of FoxO1a in EAT2-treated HSCs was
significantly higher than that in the isotype control-treated HSCs
(Figure 5C).
In addition, in the experiments that identify CD81 as a marker
for regenerating HSCs that are returning to quiescence (Figure
S1A), we observed that the CD81-expressing HSCs
(CD81
+CD48
2Lin
2SP cells) correlate with a lower phospho-Akt
level (Figure 5D) as well as a lower expression of CyclinD1 protein
(Figure 5E). More importantly, Cd81
2/2 HSCs express a higher
level of CyclinD1 protein during HSC regeneration (Figure 5F),
indicating that HSCs utilize CD81 to manage their recovery from
proliferative stimuli by down-regulating Akt activity, and subse-
quently the protein expression of CyclinD1.
Perifosine, an Alkylphospholipid, Rescues the
Engraftment Defect of Cd81
2/2 HSCs
We next investigated the activation level of Akt in the Cd81
2/2
HSCs by measuring the phospho-Akt level and found that the
Cd81
2/2 HSCs possess a higher phospho-Akt on 5FU-Day8 when
they present a hyper-proliferating phenotype (5FU-Day8). The
activity of Akt has been shown to be tightly associated with the
proliferation state of HSCs such that constitutive activation of Akt
leads to their hyper-proliferation [12] while HSCs lacking both
Akt1 and Akt2 were more quiescent [14]. However, the
consequences of both the gain and loss of Akt function was to
perturb the regeneration power of HSCs such that constitutive
activation of Akt resulted in HSC exhaustion [12] and Akt1/Akt2
loss resulted in defective hematopoiesis [14]. We therefore
reasoned that Akt activity is tightly controlled during HSC self-
renewal, and perturbing Akt activity during the recovery phase of
HSC after stress may lead to altered HSC activity. Thus, we
incubated recovering HSCs with perifosine, an Akt inhibitor, at
the stage when Cd81
2/2 HSCs show higher proliferation and
higher expression of CyclinD1. At 30 min after the perifosine
treatment (2 mg/ml), we found it returns the phospho-Akt to a
comparable level with WT cells (Figure 6A). We administered
perifosine to recipients during their recovery phase of transplan-
tation (50 mg/kg, 7 d post-transplantation) when HSCs are
presumably recovering and returning to homeostasis. Perifosine is
an alkylphospholipid that is thought to incorporate into cell
membranes, limit the accessibility of membrane signaling domains
for Akt, and subsequently block Akt activation via phosphorylation
[34]. Ten weeks later, when the transplant recipients were stably
engrafted, the regenerated marrow was extracted and transplanted
into secondary recipients. This single administration of perifosine
rescues engraftment of donor HSC-derived progeny as function-
Figure 3. Return to quiescence is delayed in Cd81
2/2 HSCs. (A) Under steady-state conditions, the proportions of proliferating of Cd81
2/2 and
wild-type (WT) HSCs are comparable. In this experiment bromodeoxyuridine (BrdU) labeling assays were performed to determine the fraction of
cycling cells in primary recipients transplanted with Cd81
2/2 and wild-type mice. Bone marrow from two to three mice was pooled per analysis and
studied over 3 d for the incorporation of BrdU. Mean values 6 SD are shown. (B) Cd81
2/2 HSCs show delay in early cell cycle exit (5FU-Day8) but a
comparable level of quiescence compared to wild type in the later stages (5FU-Day12). Proliferating HSCs were collected and purified at different
time points after 5FU administration and stained for Ki-67, a nuclear antigen associated with cell proliferation. Mean values 6 SD are shown (n=3 for
day 4, day 7, day 8, and day 12, n=2 for day 0;
#Cd81
2/2 versus WT, day 0, day 4, day 7, and day 12, not significant; **day 8, p,0.01). (C) CD81 forms
polarized clusters on HSCs transitioning to quiescence on day 8 after 5FU treatment (5FU-Day8). Scale bars represent 10 mM. (D) Compressed
distribution of CD81 on day 8 compared with day 4 or day 7 post-treatment with 5FU. Mean values 6 SD are shown (****p,0.0001). Horizontal bars
denote medium values. Approximately 20 single cell images were measured each time point with ImageJ, which gave an arbitrary value for the area
of CD81 signal within a 1 mM z-section around cell nucleus.
doi:10.1371/journal.pbio.1001148.g003
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Figure 4. CD81 monoclonal antibody triggers early cell cycle exit. (A) EAT2, a CD81 monoclonal antibody, induces clustering of CD81 on
regenerating HSCs (5FU-Day7). With CD81 antibody treatment, the localization of CD81 protein on the wild-type HSC cell membrane shows a
distinctively polarized pattern; whereas with the isotype control antibody, the pattern consists of diffuse punctuate dots. (B) The distribution of CD81
on EAT2-treated HSCs is significantly compressed by comparison with the isotype control. In this assay, single cell images were acquired, and the area
of CD81 in every acquired image was measured with ImageJ. Horizontal bars denote medium values. Mean values 6 SD are shown (***p,0.001). (C)
Engagement of CD81 proteins on proliferating HSCs (5FU-Day7) with EAT2 induces a significant fraction of HSC to enter quiescence. Ki-67 staining
was used to identify proliferating HSCs. Proportions of quiescent cells are given within the graph. (D) EAT2 induces cell cycle exit. HSCs stimulated
with 5FU were treated with EAT2 or hamster IgG (n=3 per group) and assessed for Ki-67 reactivity on day 7 post-treatment. Mean percentages 6 SD
are shown (*p,0.05).
doi:10.1371/journal.pbio.1001148.g004
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regeneration in secondary transplant recipients (Figure 6B).
Moreover, while the regeneration of Cd81
2/2 HSCs and their
progenitors are completely diminished in the untreated group
(Figure 6C and Figure S4A), those of perifosine-treated Cd81
2/2
HSCs give rise to comparable number of progeny (Figure 6C and
Figure S4B).
Interestingly, the treatment of perifosine that corrects the level of
phospho-Akt in Cd81
2/2 HSCs does not bring their proliferation
state to a comparable level with WT HSCs (unpublished data). This
indicates that although perifosine may have been limiting Akt
activity through blocking Akt from the signaling domains on
membrane as we propose CD81 may be acting, the inhibitory
kinetics are distinct from each other. Nevertheless, the dramatic
rescue of the Cd81
2/2 phenotype in the secondary recipients
suggests that CD81 functions at least in part via limiting Akt activity
during HSC self-renewal.
The Expression of CDK Inhibitors and Oxidative Stress
Genes Are Altered in Cd81
2/2 HSCs
The correlation between the loss of a tightly regulated recovery
rate and the engraftment defect of Cd81
2/2 HSCs after
proliferation stimuli suggests that CD81 is essential to maintain
the function integrity of regenerating HSCs. We thus sought to
determine the expression of CDK (cyclin dependent kinase)
inhibitors and oxidative stress genes in HSCs in homeostasis (5FU-
Day0) and during regeneration (5FU-Day8 and 5FU-Day12).
While we found that the expression of the CDK4/CDK6
inhibitors, p15, p16, and p18 [35], was not detectable from 250–
300 cell equivalents at all time points (unpublished data), the
expression of p19
Arf, a FoxO-dependent CDK inhibitor, is
significantly lower in Cd81
2/2 HSCs at the early recovery phase
(5FU-Day8) but comparable in quiescent cells (Figure 7A). In
addition, the expression of a CyclinE-CDK2 inhibitor, p21
Waf/Cip1
[35], in Cd81
2/2 HSCs was found lower only during homeostasis
(Figure 7C), suggesting an inherently imbalanced cell cycle
control. However, the expression of another CyclinE-CDK2
inhibitor, p27
Kip1 [35], was found unaltered or undetermined
(Figure 7D). Additionally, the expression of Nr4a2, a recently
identified transcription factor regulating early G1 progression [36],
was also comparable in quiescent HSCs (albeit undetectable in
regenerating HSCs) (Figure 7B), indicating loss of CD81 only
impacts part of the cell cycle regulatory circuitry.
The significantly low level of p19
Arf (Figure 7A) in regenerating
Cd81
2/2 HSCs and the translocation of FoxO1a in response to
the CD81 monoclonal antibody modulation (Figure 5B and C)
suggest altered responses to oxidative stress in the Cd81
2/2 HSCs.
Akt and FoxO proteins have been found to be essential to
maintain HSC identity and function through mediating their
resistance to oxidative stress [14,17,32]; while the expression of
p19
Arf was found to be upregulated in response to oxidative stress
and was blocked in hematopoietic progenitors lacking Atm (Ataxia
Telangiectasia Mutated protein) [11]. Thus, we sought to measure
the expression of genes that respond to oxidative stresses, Atm and
p130/Rbl2. The expression of both genes was found to be low in
homeostatic HSCs such that they are not detectable in 250 to 300
cell equivalents of RNA. However, at the later HSC regeneration
stage (5FU-Day12) when cells have returned to quiescence
(Figure 3B), the expression of both genes becomes detectable
and their expression level in Cd81
2/2 HSCs was significantly
lower (Figure 7E and F).
To further investigate whether oxidative stress may contribute
to the defective regeneration phenotypes of Cd81
2/2 HSCs, we
purified donor-derived hematopoietic progenitor cells from the
regenerating bone marrow (5FU-Day8) and analyzed the
expression level of both Atm and p130/Rbl2. Atm but not p130/
Rbl2 was found to be at a significantly lower level in Cd81
2/2
hematopoietic progenitors (Figure 7G). Taken together, these
findings suggest the oxidative stress may contribute to compromise
the function and integrity of Cd81
2/2 HSCs post-hematopoietic
regeneration.
Discussion
It is well accepted that regulation of cell cycle progression in
HSCs is critical to maintain stem cell activity [3]; however, there is
only scant understanding of the mechanisms by which proliferat-
ing HSCs return to quiescence. The results of our study delineate a
novel mechanism in which CD81, a stress-responsive membrane
protein, is upregulated in HSCs exposed to proliferative stimuli
and then acts to inhibit their otherwise unrestrained division. The
severe self-renewal defect of Cd81
2/2 HSCs after robust
proliferative stress such as transplantation suggests that the role
of CD81 in HSC self-renewal is transient and constrained in time.
The key feature of this mechanism seems to be the ability of
CD81 molecules to form specialized microdomains on the HSC
surface. These domains have been identified on other cell types,
such as lymphocytes and astrocytes, where they provide scaffolds
for signaling molecules and orchestrate the interactions of
membrane-associated proteins with effector molecules to initiate
signaling cascade that can either induce or inhibit cell proliferation
[37]. Interestingly, we found that CD81 forms a distinct patch-like,
polarized pattern when HSCs are returning to quiescence. The
membrane distribution of CD81 protein can be manipulated to
form clusters with high concentrations of monoclonal antibodies
Figure 5. FoxO1a is induced by CD81 clustering, concurrent with deactivation of Akt. (A) The phosphorylation of Akt, an indicator of Akt
activation, decreases upon CD81 clustering on proliferating HSCs. EAT2 antibody-treatment of HSCs induces a 20% reduction of phosphorylated-Akt
(pAkt), a 30% decrease of CyclinD1 expression, and no decrease of phosphorylated-ERK (p-ERK) or phosphorylated-p38 (p-p38) median fluorescence
intensity, compared with results from isotype control-treated HSCs. (B) FoxO1a but not FoxO3a is activated in HSCs in response to EAT2 antibody-
mediated CD81 clustering. In EAT2-treated HSCs, FoxO1a shows a nuclear localization phenotype on EAT2-treated cells, whereas in isotype control-
treated HSCs the majority of FoxO1a is excluded from nucleus. The localization of FoxO3a, on the other hand, shows no difference in EAT2-treated
HSC, compared to the isotype control group. The FoxO translocation was measured by Imagestream. Six representative single cells are shown. (C)
Nuclear translocation of FoxO1a in EAT2-treated HSCs is significantly higher in comparison with that in the isotype control group. An established
statistic model was employed to calculate degrees of protein nuclear localization with Pearson’s correlation coefficient and generate similarity scores
that evaluate the co-localization of FoxO signals with nucleus. Positive nuclear correlation in the single cell images was assigned when the similarity
score was more than 1 (more than 100 cells were acquired for each analysis, n=2 per group of treatment; mean values 6 SD are shown, *p,0.05). (D)
On 5FU-Day8, the level of phospho-Akt in CD81
+CD48
2Lin
2SP cells that are returning to quiescence on 5FU-Day8 is lower than that in the
CD81
+CD48
+Lin
2SP cells, a population that is proliferative. Two independent experiments were preformed, and cells from each experiment were
collected from 3 to 4 mice. (E) On 5FU-Day8, the CyclinD1 protein expression of the CD81
+CD48
2Lin
2SP cells is lower than that of the
CD81
+CD48
+Lin
2SP cells. Three independent experiments were preformed, and cells from each experiment were collected from 3 to 4 mice. (F)
Expression of cylinD1 is higher in Cd81
2/2 HSCs in 5FU-Day8 when Cd81
2/2 HSCs show a delay returning to quiescence.
doi:10.1371/journal.pbio.1001148.g005
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Figure 6. The engraftment defect of Cd81
2/2 HSCs in the secondary transplantation can be rescued by perifosine. (A) Cd81
2/2 HSCs
present an elevated phospho-Akt, when comparing to the regenerating WT HSCs at the same time point of 5FU-stimulated regeneration; while the
level of phospho-Akt can be suppressed with an in vitro perifosine treatment. Two independent experiments were performed. (B) A single perifosine
treatment during the recovery phase of the primary transplantation rescues the secondary engraftment defect of Cd81
2/2 HSCs in the peripheral
blood compartment. After stable engraftment, 500 donor HSCs (c-Kit
+Sca-1
+Lin
2CD150
+CD48
2CD45.2
+) from the primary recipients were
transplanted into lethally irradiated recipients (CD45.1) with 3610
5 WBM competitor cells. The perifosine-treated Cd81
2/2 HSCs showed viable
peripheral blood engraftment at the time when the engraftment of untreated Cd81
2/2 marrows starts to diminish. Mean values 6 SD are shown
(n=5 per group of treatment, *p,0.05, **p,0.01). (B) The engraftment defect in the secondary transplantation originates in the HSC compartment.
Secondary recipients transplanted with Cd81
2/2 HSCs lack donor-derived HSCs. (C) The secondary engraftment defect of Cd81
2/2 HSCs are rescued
by one dose of perifosine. Perifosine was given to the primary recipients at day 7 after the initial transplantation. Ten weeks later, to allow HSCs to
regenerate after the primary transplantation, HSCs were purified from the primary recipients and 500 of these donor-derived (Cd81
2/2) HSCs were
transplanted along with 3610
5 competitor cells into lethally irradiated recipients. Twenty weeks later, the donor HSC-derived progeny in these
secondary recipients were examined. Mean percentages 6 SD are shown (*p,0.05, n=4 in the wild type control, n=5 in the Cd81
2/2 group, n=4in
the wild type treated with perifosine, n=4 in the Cd81
2/2 treated with perifosine). Figure 5B shows the groups with no perifosine treatment while
Figure 5C shows the groups with perifosine treatment. The data from Figure 5B and 5C are from the same cohort but shown separately.
doi:10.1371/journal.pbio.1001148.g006
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Figure 7. Cd81
2/2 HSCs exhibit low expression of CDK inhibitors and oxidative stress genes during homeostasis and regeneration.
(A) Proliferating Cd81
2/2 HSCs (5FU-Day8) express a significantly lower level of p19
Arf while quiescent HSCs (those on 5FU-Day0 and 5FU-Day12) do
not. (B) The expression of Nr4a2 is comparable in quiescent WT and Cd81
2/2 HSCs but not detectable in proliferating HSCs. (C) Cd81
2/2 HSCs in
homeostasis present a significantly lower expression of p21
waf1/cip1 while those in regeneration do not. (D) The expression of p27Kip in both WT and
Cd81
2/2 quiescent HSCs are comparable, albeit undetectable in proliferating HSCs. (E and F) The expression of Atm and p130, the genes that respond
to oxidative stresses, are only detectable in HSCs (250 to 300 cell equivalents) in a later stage of 5FU-regeneration (5FU-Day12). The expression of
both Atm and p130 in Cd81
2/2 HSCs are significantly lower than those in WT HSCs. (G) On 5FU-Day8, the less primitive hematopoietic progenitors
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With this manipulation, only Akt, among several kinases tested
including JNK, p38, and ERK, showed a reduction in activation
in response to CD81 clustering, suggesting Akt may be closely
associated with the CD81 microdomains. Subsequently, we found
translocation of FoxO proteins are affected in response to the
clustering of CD81. However, with no known ligands for CD81, it
is unclear how CD81 is brought together to form patches. As
CD81 is thought to be able to interact with itself through its
extracellular domain [38], we thus speculate the clustering may be
spontaneous when there is an upregulated expression level of
CD81 on the cell membrane, such as we observe during HSC
regeneration (Figure 1C), which increases the local CD81 density.
Additionally the study with Cd81
2/2 HSCs in 5FU-stimulated
regeneration highlights a time point when HSCs start to return to
quiescence after the 5FU proliferative stimuli (5FU-Day8). At this
time, Cd81
2/2 HSCs showed a hyper-proliferation phenotype
with increased Akt activity, elevated expression of CyclinD1, and
decreased RNA expression of p19
Arf, indicating that CD81 acts
through Akt pathways during the proliferation phase of HSC
regeneration. Moreover, at the stage when HSCs return to
quiescence (5FU-Day12), Cd81
2/2 HSCs show significantly
decreased expression of oxidative response genes, Atm and p130/
Rbl2, suggesting that CD81 preserves the functional integrity of
regenerating HSCs partly through impacting the oxidative stress
response and possibly the intracellular level of ROS (reactive
oxygen species). Taken together, these data indicate that CD81
acts through Akt pathways to pace the cell cycle progression, the
oxidative stress response, and therefore to preserve the functional
integrity of HSCs.
Furthermore, a single in vivo treatment of an alkylphospholipid,
perifosine, to the recovering mice (during the primary transplan-
tation) rescues the defective engraftment of Cd81
2/2 HSCs as
tested in secondary transplantation. In addition to being an Akt
inhibitor, perifosine is found to act through JNK-dependent
mechanism and induce caspase-dependent apoptosis [39]. It has
been proposed to condition the regiment to treat acute
myelogenous leukemia [40,41]. However, in our study, we have
not found an altered activity of JNK in Cd81
2/2 HSCs
(unpublished data). We thus suspect that the treatment of
perifosine replaces the role of CD81 in the recovering HSCs as
microdomains that block signal transduction, and effectively
modulates Akt activity. Ultimately, to fully understand how
CD81 microdomains communicate with the Akt pathway, it will
be necessary to identify their interacting proteins in HSCs in
different stages of proliferation. More importantly, our finding that
perifosine increases HSCs engraftment may aid to improve the
human bone marrow transplantation in treating leukemic patients.
A variety of extrinsic signals provided by the HSC niche have
been reported to critically affect the ability of HSCs to maintain
stem cell integrity as well as their proliferation status [42].
However, it is unclear how any of these pathways dominantly
govern the response of the HSCs to environmental cues. Our
study suggests that when HSCs are under proliferative stress, the
CD81 microdomains orchestrate the spatial distribution of
signaling receptors on membrane as well as membrane-affiliated
intracellular molecules on HSCs, and selectively transduce the
extrinsic cues from the bone marrow niches. Future studies of the
divergent roles of the CD81 microdomains on long-term
repopulating HSCs may afford productive targets for the
regulation of stem cell growth.
Materials and Methods
Mice
All mice were housed at the Baylor College of Medicine according
to an AAALAC-approved protocol (Animal Welfare Assurance
Number A3823-1). Mice care and treatment were approved by the
Institutional Animal Care and Use Committee at the Baylor College
of Medicine (IACUC, protocol number AN-2234). 5FU (American
Pharmaceutical Partners) was injected intraperitoneally at 150 mg/
kg in PBS prior to the assays. In transplantation assays, C57BL/6
mice carrying the CD45.1 allele were used as recipients. Cd81
2/2
mice generated in a 129 background were developed in the Geha lab
[23], and were generously provided by R. Kesterson at the University
of Alabama, Birmingham, and backcrossed for at least four
generations to C57BL/6 mice carrying the CD45.2 allele.
Flow Cytometry
HSCs used in this study were purified as previously described
[43,44] based on the Hoechst33342 efflux phenotype, which
defines a characteristic side population (SP), consisting of
hematopoietic stem cells. The hoechst33342-stained whole bone
marrow cells were subjected to magnetic enrichment for lineage-
negative cells (autoMACS). Surface marker staining for Sca-1, c-
Kit, CD81(EAT2), CD48(BCM1), and lineage cocktail
(CD4,CD8, B220, Gr-1, Mac-1, and Ter119, BD Bioscience)
was performed as previously described [7]. Briefly, 2 ng/ml
antibodies were used to stain cells at the concentration of 1610
8
cells/ml. Because HSCs are known to upregulate Mac-1
expression during proliferation, the marker was excluded from
the lineage cocktail of 5FU-treated bone marrow cells. HSCs were
purified from the side population with a Mo-Flo instrument
(Beckman Coulter) based on the immunophenotype-SP, c-Kit
+,
Lin
2, and Sca-1
+ (SP
KLS) unless otherwise specified. In the EAT2
antibody-treatment experiment series, HSCs were purified based
on the expression of SP, Sca-1
+, and Lin
- (SP
SL), for the whole
bone marrow SP
KLS and SP
SL populations are highly overlapped.
In the homing assays, hematopoietic progenitors are defined as c-
Kit
+Lin
2Sca-1
+ (KLS). In the stem cell and progenitor assays, the
surface markers used to define each compartment are as follows:
LT-HSC (c-Kit
+Sca-1
+Lin
2Flk2
2CD34
2), ST-HSC (c-Kit
+Sca-
1
+Lin
2Flk2
2CD34
+), MPP (c-Kit
+Sca-1
+Lin
2Flk2
+CD34
+), CLP
(Lin
2IL7ra
+c-Kit
+Sca-1
+), CMP (Lin
2IL7ra
2c-Kit
+Sca-1
2CD-
34
+CD16/32
2), MEP (Lin
2IL7ra
2c-Kit
+Sca-1
2CD34
2CD16/
32
2), and GMP (Lin
2IL7ra
2c-Kit
+Sca-1
2CD34
+CD16/32
+). F-
ACScan and LSRII (BD Biosciences) were used for the analysis of
engraftment and cell proliferation. Engraftment was determined
by the proportion of CD45.1 and CD45.2 cells in peripheral
blood; the multilineage engraftment was based on the detection of
B220 (B cells), CD4 and CD8 (T cells), and Gr-1 and Mac-1
(myeloid lineages) [9].
Short-Term In Vitro Culture and Monoclonal Antibody
Treatment of HSCs
In the monoclonal antibody treatment experiment, HSCs were
sorted from wild type mice 7 d post-5FU treatment. Cells were
(cKit
+Lin
2Sca1
+, KLS) possess detectable level of Atm and p130 expression, and the expression level of Atm in the Cd81
2/2 progenitor cells is
significantly lower than that in the WT cells. Mean percentages 6 SD are shown (duplicate or triplicate measurement was undertaken with at least
two biological replicates, *p,0.05, **p,0.01, ***p,0.005).
doi:10.1371/journal.pbio.1001148.g007
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(clone EAT2, BD Biosciences, Cat No. 559518) or of an Armenian
Hamster IgG, k isotype control (BD Biosciences, Cat No. 553970).
Cells were then fixed in 4% paraformaldehyde for later analysis. In
the perifosine treatment experiment, HSCs were sorted and
cultured in StemSpan SFEM medium (Stem Cell Technologies,
Cat No. 09600) containing 10 ng/ml mouse SCF (Invitrogen, Cat
No. PMC2111) for 30 min, with or without the presence of 2 mg/
ml perifosine (Selleck Chemicals LLC, Cat No. S1037).
Competitive Transplantation Assay
In the Cd81
2/2 transplantation assays, given numbers (50–300/
experimental group) of donor HSCs (CD45.2) were purified,
mixed with 2 to 2.5610
5 freshly isolated whole bone marrow cells
(CD45.1) as competitors, and transplanted into individual lethally
irradiated recipients (CD45.1). In the secondary transplantations,
300 donor-derived (CD45.2) HSCs were transplanted with 2610
5
CD45.1 competitors into lethally irradiated recipients (CD45.1).
In the perifosine rescue experiments, 50 mg/kg of perifosine was
injected into primary recipients (CD45.1) 7 d via intra-peritoneal
injection after the first transplantation with 1610
6 whole bone
marrow cell from either wild-type or Cd81
2/2 mice while
Stempro34 (Invitrogen, Cat No. 10639-011) plain media (without
nutrient supplement) was injected into the control group. 10 wk
after the perifosine injection, 500 donor-derived HSCs (CD45.2
+c-
Kit
+Sca-1
+Lin
2CD150
+CD48
2 bone marrow cells) were purified
and transplanted into lethally irradiated secondary recipients
(CD45.1) with 3610
5 whole bone marrow cells as competitors
(CD45.1).
Proliferation Assays of HSCs
To assess HSC proliferation under homeostasis, we performed
BrdU labeling as previously described [45]. Three days before the
analysis, mice were intraperitoneally injected with BrdU (5 mg/
30 g of mouse body weight) and given BrdU-containing drinking
water 1 mg/ml) for 3 d. Two or three mice per genotype were
pooled for each experiment. SP
KLS cells were isolated and mixed
with 25,000 carrier cells (B220
+ or Gr1
+) for BrdU intracellular
staining (BrdU Flow kit, BD Biosciences). In the 5FU-stimulated
proliferation experiments, Ki-67 staining was employed to
measure cell proliferation because BrdU staining is not compatible
with 5FU treatment owing to excessive toxicity. The 5FU-treated
HSCs were isolated and mixed with 25,000 carrier cells (B220
+
cells). Samples were then fixed with Cytoperm/CytoFix solution
and permeablized with the Cytoperm solution (BD Bioscience)
before the Ki-67 intracellular staining with Ki-67 (BD Biosciences,
Cat. No. 612472). The background of each Ki-67 staining
experiment varied, so that the positive and negative gates were
determined with the isotype control in conjunction with the carrier
cells in each sample.
Immunostaining and Deconvolution Microscopy
Single cell images were acquired by applied precision
deconvolution microscopy. In the immunostaining experiments,
HSCs were first purified from Mo-Flo (Beckman Coulter) and
cytospun (Cytopro, Wescor) onto glass slides. Cells were fixed with
4% paraformaldehyde and subjected to immunostaining of surface
markers. CD81 expression was detected with the monoclonal
antibody EAT2 (BD Biosciences, Cat. No. 559519). For intracel-
lular staining, HSCs were permeabilized by either ethanol or 0.1X
Perm buffer IV (BD Biosciences, Cat No. 560746). HSCs were
then labeled with either amine reactive Alexa488 carboxylic acid,
succinimidyl ester (Invitrogen, Cat. No. A-20100), or Pacific Blue
carboxylic acid, succinimidyl ester (Invitrogen, Cat. No. P-10163).
HSCs were mixed with spleenocytes as carrier cells before staining.
The intracellular staining of phospho-Akt (p-Akt Thr308, clone
C31E5E, Cell Signaling Technology), phospho-ERK (p-ERK
Thr202/Tyr204, clone D13.14.4E, Cell Signaling Technology),
phospho-p38 (p-p38 Thr180/Tyr182, rabbit polyclonal, Cat.
No. 9211, Cell Signaling Technology), phospho-JNK (p-SAPK/
JNK Thr183/Tyr185, rabbit polyclonal Cat. No. 9251, Cell
Signaling Technology), FoxO1a (rabbit polyclonal, Cat.
No. ab39670, Abcam Inc.), and FoxO3a (clone 75D8, Cell
Signaling Technology) was quantified with an HRP-conjugated
goat anti-rabbit antibody, followed by signaling amplification
yielding Alexa647 fluorescence. Intracellular staining was then
detected with an LSRII instrument (BD Bioscience). In the
experiments that compare the level of p-Akt between wild-type
and Cd81
2/2 HSCs, cells were stained with Alexa647-conjugated
antibody (pAkt Thr308, clone C31E5E, Cell Signaling Technol-
ogy). The protein expression of CyclinD1 was detected with a
FITC-conjugated CyclinD1 antibody (Clone SP4, Abcam Inc.).
Differences in protein expression levels were assessed by
comparing ratios of median fluorescence intensities. The localiza-
tion of FoxOs in single HSCs was determined with ImageStream
flow cytometry.
ImageStream Flow Cytometry
The ImageStream is a multispectral imaging flow cytometer
that generates high resolution images of cells at a rate of over 100
cells per second [33]. Spectral compensation and background
correction was performed, and images were analyzed with the
IDEAS image analysis software. To identify and compare HSCs
that had been treated with different agents at the same acquisition,
we bar-coded the HSCs with either Alexa488 or Pacific Blue
carboxylic acid succinimidyl ester. Approximately 50,000 images
per sample were collected to obtain the largest number of the
,0.5% HSC cells present in each sample.
Statistics
For comparison of treatment group differences, we used the
unpaired two-tailed Student t test. All error bars indicate standard
errors of the mean (SEM), while p values indicated with asterisks
were considered significant at the p=0.05 level or lower. To
analyze the nuclear localization of FoxO transcription factors, we
employed an established statistic model that calculates degrees of
protein nuclear localization with Pearson’s correlation coefficient
[33]. We assigned a positive nuclear correlation an arbitrary value
1, although the positive correlations may range from 0 to 5.
RNA Isolation and Q-RT-PCR Analysis
HSC collection at each time point: 3,000 to 5,000 donor-
derived HSCs (CD45.2
+SP
KLS) were collected on 5FU-Day0,
while 10,000 HSCs were collected on 5FU-Day8 and 5FU-Day12.
Total RNA was isolated from HSCs using RNeasy Mini Kit
(Qiagen, Cat. No. 74104) that provides in-column DNaseI
treatment during column purification. First strand synthesis was
performed with Superscript VILO cDNA synthesis kit that
includes SuperscriptIII reverse transcriptase and random hexa-
mers (Invitrogen, Cat. No. 11754-050). An equivalent of 250 to
330 cells were subjected to each Q-RT-PCR reaction. Q-RT-PCR
was performed with pre-validated Taqman probe sets (Applied
Biosystems) on a 7300 Real-Time PCR system for 55 cycles. A
mouse internal GAPD control was included in every reaction for
normalization. The threshold cycle was determined with software
provided by the manufacturer, and expression was measured for
each assay relative to the GAPD internal standard (DCt). Assays
were performed in triplicate (technical replicates) and each
CD81 Is Essential for HSCs Returning to Quiescence
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Relative expression between two cell populations was calculated
by subtracting the DCt values (DDCt). Fold differences were
calculated as 2ˆ(DDCt) when DDCt . 0o r2(2ˆ(2DDCt)) when
DDCt , 0.
Supporting Information
Figure S1 CD81 marks regenerating HSCs. (A) The bone
marrow side population (SP) expands in response to single
administration of 5FU. Under homeostasis, 0.1% of Lineage-
depleted bone marrow cells (Lin
2: CD4
2, CD8
2, B220
2, Mac1
2,
Gr1
2, and Ter119
2) are side population (SP), while on day 7 after
the 5FU treatment, this percentage increases to 1.8%. (B)
CD81
+SP cells possess a higher Hoechst dye efflux capacity (and
hence lower fluorescence), a phenotype associated with stem cell
activity, in contrast to CD48
+SP cells. CD81 and CD48 define
discrete subpopulations within the 5FU-Day7 SP population.
CD48
+CD81
2 marks the lower to tip SP fraction (55% of tip-SP
cells), while CD81
2CD48
+ marks the upper-to-shoulder fraction
(19% of tip-SP cells). Cd81
+CD48
+ marks the intermediate SP
population (23% of tip-SP cells).
(PDF)
Figure S2 Cd81
2/2 HSCs showed comparable contribution to
blood lineages, colony forming ability and homing ability after the
primary competitive transplantation. (A) Cd81
2/2 HSCs were able
to generate comparable portion of blood lineages in the recipients
of the primary competitive transplantation, indicating the multi-
lineage differentiation ability of Cd81
2/2 HSC is intact.
Representative cohort shown here is the blood engraftment at
the 14th week post whole bone marrow transplantation (n=28 for
wild-type, n=29 for Cd81
2/2). (B) Post the primary transplanta-
tion, Cd81
2/2 HSCs showed comparably ability to generate
colonies albeit presenting a defective phenotype in the recipients of
the secondary transplantation. After the primary transplantation,
single HSCs were purified and placed in M3434 metholcult media
for assaying colony-forming ability. 48-96 single cells were scored
for colony forming in each set of single M3434 culture. Mean
value 6 SD findings are shown (n=3 for both WT and Cd81
2/2).
(C) To test whether Cd81
2/2 HSCs are defective in their ability to
reach the bone marrow niche after the primary transplantation,
we performed a homing assay, using Cd81
2/2 HSC from the
recipient mice of the primary competitive transplantation assay.
The CFSE based homing assay was modified from a previous
protocol [1]. Briefly, the CD45.2 nucleated bone marrow cells
from the original transplant recipients were magnetically purified
and labeled with a fluorescent lipid dye, PKH2 Green Fluorescent
Cell Linker (Sigma). 2610
7 cells were then transplanted lethally
irradiated mice. After 12 h, the recipient mice were sacrificed and
one leg (a tibia and a femur) was collected for analysis. The homed
donor progenitor cells were measured as the percentage of
fluorescence-labeled KLS (c-Kit
+ Lineage- and Sca-1
+) cells in
recipient bone marrow. Mean 6 SD findings are shown (n=4 for
wild-type and 3 for Cd81
2/2 transplantation). CFSE is the
abbreviation of carboxyfluorescein succinimidyl ester, a fluores-
cence dye labeling cell membrane).
(PDF
Figure S3 Gating schemes of the Ki-67 detection and of the
expression level of p-Akt. (A) In the 5FU time course study,
proliferating cells of HSCs were measured by the expression of Ki-
67. HSCs were purified based on the properties of Hoechst33342
efflux (SP) and marker expression including c-Kit
+, Sca-1
+, and
Lin- (SPKLS), as well as the expression of CD45 marker that
distinguish donor-derived HSCs (CD45.2
+) from the competitors
(CD45.1
+). Ki-67 gates were drawn based on the internal controls
of each analysis, which is non-stimulated spleenocytes. (B) The
scheme of color-coated HSCs in the analysis of p-Akt level. Wild-
type or Cd81
2/2 HSCs were sorted based on the markers: SPKLS
and CD45.2
+CD45.1
2. Cells were then fixed with 4% parafor-
maldehyde and permeablized with 0.16 Perm Buffer IV (BD
Biosciences, Cat No. 560746) during which Cd81
2/2 cells were
color coated with an amine-reactive pacific blue succinimidyl ester
(Invitrogen, Cat No. P10163). (B) Wild-type and Cd81
2/2 cells
were pooled before the staining and analysis of level of phospho-
Akt (p-Akt). The level of p-Akt was detected with either an
Alexa647-conjugated phospho-Akt (Thr308) monoclonal antibody
(Cell signaling Technology, Cat No. 3375), or non-conjugated
phosphor-Akt (Thr308) monoclonal antibody (Cell Signaling
Technology, Cat No. 2965) with a HRP-conjugated, goat ant-
rabbit secondary antibody that is detected with a Alexa647-
tyramide signal amplification kit (Invitrogen, Cat No. T20926).
Representative data shown in Figure 6 is the one detected with the
Alexa647-conjufated p-Akt antibody.
(PDF)
Figure S4 The engraftment defect of Cd81
2/2 progenitors in the
secondary transplantation can be rescued by perifosine. (A) The
engraftment defect in the secondary transplantation is found in the
progenitor compartments. Analysis of progenitor compartments
was preformed as previously described [2,3]. Secondary recipients
transplanted with Cd81
2/2 HSC lack progenitors such as MPP
(multipotent progenitors), CMP (common myeloid progenitors,
Lin
2cKit
+Sca1
2Il7ra
2CD34
+CD16/32
2), CLP (common lym-
phoid progenitors, Lin
2cKit
+Sca1
+Il7ra
+), MEP (megakaryocyte-
erythrocyte progenitors, Lin
2cKit
+Sca1
2Il7ra
2CD34
2CD16/
32
2), and GMP (Granulocutemacrophage progenitors, Lin
2cK-
it
+Sca1
2Il7ra
2CD34
+CD16/32
+). (B) The secondary engraftment
defect of Cd81-/- progenitors is rescued by one dose of perifosine
(50 mg/kg).Cd81
2/2 HSCs that had been exposed to the perifosine
treatment gave rise to comparable numbers of stem and progenitor
progeny, except for a significantly lower CLP engraftment. Mean
percentage 6 SD are shown (*p,0.05, n=4 in the wild-type
control, n=5 in the Cd81
2/2 group, n=4 in the wild-type treated
with perifosine, n=4 in the Cd81
2/2 treated with perifosine). (C)
HSC and MPP gating schemes. Bone marrows from secondary
recipients that were transplanted with either wild-type or Cd81
2/2
HSCs, with or without perifosine treatment, were analyzed for the
donor-derived (CD45.2
+) HSCs and progenitors. Examples shown
here are the gating scheme of LT-HSC (Lin
2cKit
+
Sca1
+Flk2
2CD34
2), ST-HSC (Lin
2cKit
+Sca1
+Flk2-CD34
+), and
MPP (Lin
2cKit
+Sca1
+Flk2
+CD34
+).
(PDF)
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